3-aminobenzamide has been researched along with Injury, Myocardial Reperfusion in 14 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pharmacological protection from myocardial reperfusion injury, despite plenty of approaches, has still not been realized in humans." | 1.36 | Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size. ( Barthuber, C; Bergt, S; Bohnenberg, K; Mersmann, J; Nöldge-Schomburg, GE; Roesner, JP; Szabo, C; Zacharowski, K, 2010) |
| "During myocardial reperfusion injury, oxidative stress induces DNA damage and activation of the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP-1), resulting in cardiovascular dysfunction." | 1.33 | Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration. ( Hake, PW; Kaplan, J; O'Connor, M; Zingarelli, B, 2005) |
| "After 60 min of hypothermic cardiac arrest, reperfusion was started after application of either saline vehicle (control, n = 6), or INO-1001 (1 mg/kg), a potent PARP inhibitor (n = 6)." | 1.32 | INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation. ( Bährle, S; Cziráki, A; Flechtenmacher, C; Gries, A; Hagl, S; Heger, U; Mandera, S; Seres, L; Soós, P; Szabó, C; Szabó, G; Vahl, CF; Zsengellér, Z, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (21.43) | 18.2507 |
| 2000's | 7 (50.00) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eltze, T | 1 |
| Boer, R | 1 |
| Wagner, T | 1 |
| Weinbrenner, S | 1 |
| McDonald, MC | 2 |
| Thiemermann, C | 4 |
| Bürkle, A | 1 |
| Klein, T | 1 |
| Nishizawa, K | 1 |
| Yanagida, S | 1 |
| Yamagishi, T | 1 |
| Takayama, E | 1 |
| Bessho, M | 1 |
| Kusuhara, M | 1 |
| Adachi, T | 1 |
| Ohsuzu, F | 1 |
| Zhang, LQ | 1 |
| Qi, GX | 1 |
| Jiang, DM | 1 |
| Tian, W | 1 |
| Zou, JL | 1 |
| Yamazaki, K | 1 |
| Miwa, S | 1 |
| Ueda, K | 1 |
| Tanaka, S | 1 |
| Toyokuni, S | 1 |
| Unimonh, O | 1 |
| Nishimura, K | 1 |
| Komeda, M | 1 |
| Kaplan, J | 1 |
| O'Connor, M | 1 |
| Hake, PW | 1 |
| Zingarelli, B | 2 |
| Cuzzocrea, S | 1 |
| Zsengellér, Z | 3 |
| Salzman, AL | 1 |
| Szabó, C | 6 |
| Bowes, J | 2 |
| Ruetten, H | 1 |
| Martorana, PA | 1 |
| Stockhausen, H | 1 |
| Piper, J | 1 |
| Liaudet, L | 1 |
| Yang, Z | 1 |
| Al-Affar, EB | 1 |
| Rehberg, S | 1 |
| Traber, DL | 1 |
| Roesner, JP | 1 |
| Mersmann, J | 1 |
| Bergt, S | 1 |
| Bohnenberg, K | 1 |
| Barthuber, C | 1 |
| Nöldge-Schomburg, GE | 1 |
| Zacharowski, K | 1 |
| Szabó, G | 2 |
| Soós, P | 2 |
| Mandera, S | 1 |
| Heger, U | 2 |
| Flechtenmacher, C | 2 |
| Bährle, S | 2 |
| Seres, L | 1 |
| Cziráki, A | 1 |
| Gries, A | 1 |
| Vahl, CF | 1 |
| Hagl, S | 2 |
| Maier, C | 1 |
| Scheuerle, A | 1 |
| Hauser, B | 1 |
| Schelzig, H | 1 |
| Radermacher, P | 1 |
| Kick, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Randomized, Placebo-Controlled, Single-Blind, Multi-Center Dose-Escalation Study to Evaluate Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Administration of INO-1001 in Subjects With ST-Elevation Myocardia[NCT00271765] | Phase 2 | 40 participants | Interventional | 2004-01-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
14 other studies available for 3-aminobenzamide and Injury, Myocardial Reperfusion
| Article | Year |
|---|---|
Imidazoquinolinone, imidazopyridine, and isoquinolindione derivatives as novel and potent inhibitors of the poly(ADP-ribose) polymerase (PARP): a comparison with standard PARP inhibitors.
Topics: Animals; Cell Line; Cell Line, Tumor; Fibroblasts; Humans; Imidazoles; Isoquinolines; Kinetics; Male | 2008 |
Continuous inhibition of poly(ADP-ribose) polymerase does not reduce reperfusion injury in isolated rat heart.
Topics: Animals; Apoptosis; Benzamides; Blotting, Western; Cardiotonic Agents; Enzyme Inhibitors; In Vitro T | 2013 |
Increased poly(ADP-ribosyl)ation in peripheral leukocytes and the reperfused myocardium tissue of rats with ischemia/reperfusion injury: prevention by 3-aminobenzamide treatment.
Topics: Animals; Benzamides; Enzyme Activation; Enzyme Inhibitors; Leukocytes; Male; Myocardial Reperfusion | 2012 |
Prevention of myocardial reperfusion injury by poly(ADP-ribose) synthetase inhibitor, 3-aminobenzamide, in cardioplegic solution: in vitro study of isolated rat heart model.
Topics: Animals; Apoptosis; Benzamides; Cardiac Surgical Procedures; Cardioplegic Solutions; Disease Models, | 2004 |
Inhibitors of poly (ADP-ribose) polymerase ameliorate myocardial reperfusion injury by modulation of activator protein-1 and neutrophil infiltration.
Topics: Animals; Benzamides; Caspase 3; Caspases; Cell Adhesion Molecules; Cells, Cultured; Endothelium, Vas | 2005 |
Protection against myocardial ischemia and reperfusion injury by 3-aminobenzamide, an inhibitor of poly (ADP-ribose) synthetase.
Topics: Adenosine Triphosphate; Animals; Benzamides; Cells, Cultured; Creatine Kinase; Endothelium, Vascular | 1997 |
Reduction of myocardial reperfusion injury by an inhibitor of poly (ADP-ribose) synthetase in the pig.
Topics: Animals; Benzamides; Blood Pressure; Cell Death; Cells, Cultured; Enzyme Inhibitors; Eukaryotic Cell | 1998 |
Inhibitors of poly (ADP-ribose) synthetase protect rat cardiomyocytes against oxidant stress.
Topics: Aminobenzoates; Animals; Benzamides; Cell Death; Cell Line; Enzyme Inhibitors; Heart; Hydrogen Perox | 1999 |
Myocardial ischemic preconditioning in rodents is dependent on poly (ADP-ribose) synthetase.
Topics: Animals; Benzamides; Enzyme Inhibitors; Immunohistochemistry; Interleukin-10; Interleukin-12; Ischem | 2001 |
Increased inotropism following PARP inhibition in the setting of myocardial reperfusion injury: another piece in the jigsaw?
Topics: Animals; Cardiotonic Agents; Indoles; Myocardial Infarction; Myocardial Reperfusion Injury; Poly(ADP | 2010 |
Therapeutic injection of PARP inhibitor INO-1001 preserves cardiac function in porcine myocardial ischemia and reperfusion without reducing infarct size.
Topics: Animals; Cardiotonic Agents; Hemodynamics; Indoles; Ischemic Preconditioning, Myocardial; Male; Myoc | 2010 |
INO-1001 a novel poly(ADP-ribose) polymerase (PARP) inhibitor improves cardiac and pulmonary function after crystalloid cardioplegia and extracorporal circulation.
Topics: Acetylcholine; Adenosine Diphosphate Ribose; Animals; Disease Models, Animal; Dogs; Enzyme Inhibitor | 2004 |
Poly(ADP-ribose) polymerase inhibition attenuates biventricular reperfusion injury after orthotopic heart transplantation.
Topics: Animals; Coronary Circulation; Dogs; Endothelium, Vascular; Heart Transplantation; Heart Ventricles; | 2005 |
The selective poly(ADP)ribose-polymerase 1 inhibitor INO1001 reduces spinal cord injury during porcine aortic cross-clamping-induced ischemia/reperfusion injury.
Topics: Acid-Base Equilibrium; Animals; Female; Indoles; Male; Myocardial Reperfusion Injury; Nissl Bodies; | 2007 |